A Study of LY3841136 in Overweight and Obese Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT06345066
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Administered SC.
  • LY3841136 — DRUG
    Administered SC.
  • Placebo — DRUG
    Administered SC.

Study Details

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

Key Dates

Start date
Apr 3, 2024
Status verified
Oct 2025
Primary completion
Sep 29, 2025
Completion
Sep 29, 2025

Study Design

Enrollment
96 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3841136 + Tirzepatide
    LY3841136 administered subcutaneously (SC) in combination with tirzepatide given SC.
  • Placebo Comparator: Placebo + Tirzepatide
    Placebo administered SC in combination with tirzepatide given SC.

Primary Outcome Measure

Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration [ Time Frame: Baseline up to 42 weeks ]

Locations (3)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117-
Fortrea Clinical Research UnitDallasTexas75247-
Fortrea Clinical Research UnitMadisonWisconsin53704-

Find similar trials in Daytona Beach, FL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Fortrea Clinical Research Unit· Daytona Beach, FLFortrea Clinical Research Unit· Dallas, TXFortrea Clinical Research Unit· Madison, WI

Related Studies